Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease

2002 ◽  
Vol 52 (1) ◽  
pp. 62-67 ◽  
Author(s):  
Wiesje M. Van Der Flier ◽  
Dominique M. J. Van Den Heuvel ◽  
Annelies W. E. Weverling-Rijnsburger ◽  
Eduard L. E. M. Bollen ◽  
Rudi G. J. Westendorp ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Magnetization Transfer ◽  
Normal Aging ◽  
Magnetization Transfer Imaging

Magnetization transfer imaging of gray and white matter in mild cognitive impairment and Alzheimer's disease

2006 ◽  
Vol 27 (12) ◽  
pp. 1757-1762 ◽  
Author(s):  
A.C.G.M. van Es ◽  
W.M. van der Flier ◽  
F. Admiraal-Behloul ◽  
H. Olofsen ◽  
E.L.E.M. Bollen ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
White Matter ◽  
Magnetization Transfer ◽  
Magnetization Transfer Imaging

scholarly journals Working Memory and Executive Function Decline across Normal Aging, Mild Cognitive Impairment, and Alzheimer’s Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Anna-Mariya Kirova ◽  
Rebecca B. Bays ◽  
Sarita Lagalwar
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Working Memory ◽  
Cognitive Impairment ◽  
Executive Function ◽  
Mild Cognitive Impairment ◽  
Executive Dysfunction ◽  
Normal Aging ◽  
Future Research ◽  
Neurological Differences

Alzheimer’s disease (AD) is a progressive neurodegenerative disease marked by deficits in episodic memory, working memory (WM), and executive function. Examples of executive dysfunction in AD include poor selective and divided attention, failed inhibition of interfering stimuli, and poor manipulation skills. Although episodic deficits during disease progression have been widely studied and are the benchmark of a probable AD diagnosis, more recent research has investigated WM and executive function decline during mild cognitive impairment (MCI), also referred to as the preclinical stage of AD. MCI is a critical period during which cognitive restructuring and neuroplasticity such as compensation still occur; therefore, cognitive therapies could have a beneficial effect on decreasing the likelihood of AD progression during MCI. Monitoring performance on working memory and executive function tasks to track cognitive function may signal progression from normal cognition to MCI to AD. The present review tracks WM decline through normal aging, MCI, and AD to highlight the behavioral and neurological differences that distinguish these three stages in an effort to guide future research on MCI diagnosis, cognitive therapy, and AD prevention.

P3-175: Relationships between global cognitive dysfunction and PET biomarkers in normal aging, mild cognitive impairment and Alzheimer's disease

2012 ◽  
Vol 8 (4S_Part_14) ◽  
pp. P514-P514
Author(s):  
Eun Hyun Seo ◽  
Dong Young Lee ◽  
IL Han Choo ◽  
Bo Kyung Sohn ◽  
Jee Wook Kim ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Dysfunction ◽  
Normal Aging
Sign in / Sign up

Export Citation Format

Share Document